Pharmacokinetics of meglumine antimoniate after administration of a multiple dose in dogs experimentally infected with Leishmania infantum
Pharmacokinetics of meglumine antimoniate in dogs with experimentally induced leishmaniosis has been investigated. After infection, dogs received a dose of 75 mg kg −1 of meglumine antimoniate twice daily by subcutaneous injection for 10 days. Blood samples were collected throughout the treatment. N...
Gespeichert in:
| Veröffentlicht in: | Veterinary parasitology 1998-02, Vol.75 (1), p.33-40 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 40 |
|---|---|
| container_issue | 1 |
| container_start_page | 33 |
| container_title | Veterinary parasitology |
| container_volume | 75 |
| creator | Valladares, Josep-Enric Riera, Cristina Alberola, Jordi Gállego, Montserrat Portús, Montserrat Cristòfol, Carles Franquelo, Carme Arboix, Margarita |
| description | Pharmacokinetics of meglumine antimoniate in dogs with experimentally induced leishmaniosis has been investigated. After infection, dogs received a dose of 75 mg kg
−1 of meglumine antimoniate twice daily by subcutaneous injection for 10 days. Blood samples were collected throughout the treatment. No statistical differences were found in the kinetic behaviour of the drug administered as a single dose to healthy dogs and that administered as a multiple dose to infected animals. However, peak plasma concentrations (
C
max) of 30.8±12.8
μg ml
−1 found after this dosage regimen were higher than those observed after the single dose administration of 100 mg kg
−1 24 h
−1. Furthermore, sustained antimony concentrations of 1.14±0.52
μg Sb ml
−1 were detected throughout the treatment. No signs of toxicity were found in the animals treated indicating that this regimen would be very appropriate to treat canine leishmaniosis. |
| doi_str_mv | 10.1016/S0304-4017(97)00193-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_17292685</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0304401797001933</els_id><sourcerecordid>17292685</sourcerecordid><originalsourceid>FETCH-LOGICAL-c391t-6570d1561c874c23546b1719f3da89ad54df6af7ab6ceb62af9ad21f3275c1c53</originalsourceid><addsrcrecordid>eNqFUUFuFDEQtBBR2ASeEMknBIcBezy21yeEokCQViJS4Gx57XbWMB4vtgfIF_JqPNlVrpy61VXdpa5C6IKSd5RQ8f6WMDJ0A6HyjZJvCaGKdewZWtG1ZF3POXmOVk-UF-islB-EkIEIeYpOFReCqH6FHm52Jkdj088wQQ224ORxhLtxjm2AzVRDTFMwtfW-QsbGNSCUmk0NaVrYBsd5rGE_AnapAA5Tq3cFw9895BBhqmYc79vYg63g8J9Qd3gDoeyiaZcXoMnM8SU68WYs8OpYz9H3T1ffLq-7zdfPXy4_bjrLFK2d4JI4ygW1aznYnvFBbKmkyjNn1so4PjgvjJdmKyxsRW98G_bUs15ySy1n5-j14e4-p18zlKpjKBbG0UyQ5qKp7FUv1guRH4g2p1IyeL1v_5h8rynRSwb6MQO9GKyV1I8ZaNb2Lo4C8zaCe9o6mt7wDwcc2pe_A2RdbIDJggu5WaRdCv9R-AeTJ5ok</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17292685</pqid></control><display><type>article</type><title>Pharmacokinetics of meglumine antimoniate after administration of a multiple dose in dogs experimentally infected with Leishmania infantum</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Valladares, Josep-Enric ; Riera, Cristina ; Alberola, Jordi ; Gállego, Montserrat ; Portús, Montserrat ; Cristòfol, Carles ; Franquelo, Carme ; Arboix, Margarita</creator><creatorcontrib>Valladares, Josep-Enric ; Riera, Cristina ; Alberola, Jordi ; Gállego, Montserrat ; Portús, Montserrat ; Cristòfol, Carles ; Franquelo, Carme ; Arboix, Margarita</creatorcontrib><description>Pharmacokinetics of meglumine antimoniate in dogs with experimentally induced leishmaniosis has been investigated. After infection, dogs received a dose of 75 mg kg
−1 of meglumine antimoniate twice daily by subcutaneous injection for 10 days. Blood samples were collected throughout the treatment. No statistical differences were found in the kinetic behaviour of the drug administered as a single dose to healthy dogs and that administered as a multiple dose to infected animals. However, peak plasma concentrations (
C
max) of 30.8±12.8
μg ml
−1 found after this dosage regimen were higher than those observed after the single dose administration of 100 mg kg
−1 24 h
−1. Furthermore, sustained antimony concentrations of 1.14±0.52
μg Sb ml
−1 were detected throughout the treatment. No signs of toxicity were found in the animals treated indicating that this regimen would be very appropriate to treat canine leishmaniosis.</description><identifier>ISSN: 0304-4017</identifier><identifier>EISSN: 1873-2550</identifier><identifier>DOI: 10.1016/S0304-4017(97)00193-3</identifier><identifier>PMID: 9566092</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Analysis of Variance ; Animals ; Antibodies, Protozoan - blood ; Antiprotozoal Agents - administration & dosage ; Antiprotozoal Agents - pharmacokinetics ; Antiprotozoal Agents - therapeutic use ; Control methods—Protozoa ; Dog ; Dog Diseases ; Dogs ; Drug Administration Schedule ; Injections, Subcutaneous ; Leishmania infantum ; Leishmaniasis, Visceral - blood ; Leishmaniasis, Visceral - drug therapy ; Leishmaniasis, Visceral - veterinary ; Male ; Meglumine - administration & dosage ; Meglumine - pharmacokinetics ; Meglumine - therapeutic use ; Meglumine Antimoniate ; Metabolic Clearance Rate ; Organometallic Compounds - administration & dosage ; Organometallic Compounds - pharmacokinetics ; Organometallic Compounds - therapeutic use ; Pharmacokinetics</subject><ispartof>Veterinary parasitology, 1998-02, Vol.75 (1), p.33-40</ispartof><rights>1998 Elsevier Science B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c391t-6570d1561c874c23546b1719f3da89ad54df6af7ab6ceb62af9ad21f3275c1c53</citedby><cites>FETCH-LOGICAL-c391t-6570d1561c874c23546b1719f3da89ad54df6af7ab6ceb62af9ad21f3275c1c53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0304-4017(97)00193-3$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9566092$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Valladares, Josep-Enric</creatorcontrib><creatorcontrib>Riera, Cristina</creatorcontrib><creatorcontrib>Alberola, Jordi</creatorcontrib><creatorcontrib>Gállego, Montserrat</creatorcontrib><creatorcontrib>Portús, Montserrat</creatorcontrib><creatorcontrib>Cristòfol, Carles</creatorcontrib><creatorcontrib>Franquelo, Carme</creatorcontrib><creatorcontrib>Arboix, Margarita</creatorcontrib><title>Pharmacokinetics of meglumine antimoniate after administration of a multiple dose in dogs experimentally infected with Leishmania infantum</title><title>Veterinary parasitology</title><addtitle>Vet Parasitol</addtitle><description>Pharmacokinetics of meglumine antimoniate in dogs with experimentally induced leishmaniosis has been investigated. After infection, dogs received a dose of 75 mg kg
−1 of meglumine antimoniate twice daily by subcutaneous injection for 10 days. Blood samples were collected throughout the treatment. No statistical differences were found in the kinetic behaviour of the drug administered as a single dose to healthy dogs and that administered as a multiple dose to infected animals. However, peak plasma concentrations (
C
max) of 30.8±12.8
μg ml
−1 found after this dosage regimen were higher than those observed after the single dose administration of 100 mg kg
−1 24 h
−1. Furthermore, sustained antimony concentrations of 1.14±0.52
μg Sb ml
−1 were detected throughout the treatment. No signs of toxicity were found in the animals treated indicating that this regimen would be very appropriate to treat canine leishmaniosis.</description><subject>Analysis of Variance</subject><subject>Animals</subject><subject>Antibodies, Protozoan - blood</subject><subject>Antiprotozoal Agents - administration & dosage</subject><subject>Antiprotozoal Agents - pharmacokinetics</subject><subject>Antiprotozoal Agents - therapeutic use</subject><subject>Control methods—Protozoa</subject><subject>Dog</subject><subject>Dog Diseases</subject><subject>Dogs</subject><subject>Drug Administration Schedule</subject><subject>Injections, Subcutaneous</subject><subject>Leishmania infantum</subject><subject>Leishmaniasis, Visceral - blood</subject><subject>Leishmaniasis, Visceral - drug therapy</subject><subject>Leishmaniasis, Visceral - veterinary</subject><subject>Male</subject><subject>Meglumine - administration & dosage</subject><subject>Meglumine - pharmacokinetics</subject><subject>Meglumine - therapeutic use</subject><subject>Meglumine Antimoniate</subject><subject>Metabolic Clearance Rate</subject><subject>Organometallic Compounds - administration & dosage</subject><subject>Organometallic Compounds - pharmacokinetics</subject><subject>Organometallic Compounds - therapeutic use</subject><subject>Pharmacokinetics</subject><issn>0304-4017</issn><issn>1873-2550</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUUFuFDEQtBBR2ASeEMknBIcBezy21yeEokCQViJS4Gx57XbWMB4vtgfIF_JqPNlVrpy61VXdpa5C6IKSd5RQ8f6WMDJ0A6HyjZJvCaGKdewZWtG1ZF3POXmOVk-UF-islB-EkIEIeYpOFReCqH6FHm52Jkdj088wQQ224ORxhLtxjm2AzVRDTFMwtfW-QsbGNSCUmk0NaVrYBsd5rGE_AnapAA5Tq3cFw9895BBhqmYc79vYg63g8J9Qd3gDoeyiaZcXoMnM8SU68WYs8OpYz9H3T1ffLq-7zdfPXy4_bjrLFK2d4JI4ygW1aznYnvFBbKmkyjNn1so4PjgvjJdmKyxsRW98G_bUs15ySy1n5-j14e4-p18zlKpjKBbG0UyQ5qKp7FUv1guRH4g2p1IyeL1v_5h8rynRSwb6MQO9GKyV1I8ZaNb2Lo4C8zaCe9o6mt7wDwcc2pe_A2RdbIDJggu5WaRdCv9R-AeTJ5ok</recordid><startdate>19980215</startdate><enddate>19980215</enddate><creator>Valladares, Josep-Enric</creator><creator>Riera, Cristina</creator><creator>Alberola, Jordi</creator><creator>Gállego, Montserrat</creator><creator>Portús, Montserrat</creator><creator>Cristòfol, Carles</creator><creator>Franquelo, Carme</creator><creator>Arboix, Margarita</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>M7N</scope></search><sort><creationdate>19980215</creationdate><title>Pharmacokinetics of meglumine antimoniate after administration of a multiple dose in dogs experimentally infected with Leishmania infantum</title><author>Valladares, Josep-Enric ; Riera, Cristina ; Alberola, Jordi ; Gállego, Montserrat ; Portús, Montserrat ; Cristòfol, Carles ; Franquelo, Carme ; Arboix, Margarita</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c391t-6570d1561c874c23546b1719f3da89ad54df6af7ab6ceb62af9ad21f3275c1c53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Analysis of Variance</topic><topic>Animals</topic><topic>Antibodies, Protozoan - blood</topic><topic>Antiprotozoal Agents - administration & dosage</topic><topic>Antiprotozoal Agents - pharmacokinetics</topic><topic>Antiprotozoal Agents - therapeutic use</topic><topic>Control methods—Protozoa</topic><topic>Dog</topic><topic>Dog Diseases</topic><topic>Dogs</topic><topic>Drug Administration Schedule</topic><topic>Injections, Subcutaneous</topic><topic>Leishmania infantum</topic><topic>Leishmaniasis, Visceral - blood</topic><topic>Leishmaniasis, Visceral - drug therapy</topic><topic>Leishmaniasis, Visceral - veterinary</topic><topic>Male</topic><topic>Meglumine - administration & dosage</topic><topic>Meglumine - pharmacokinetics</topic><topic>Meglumine - therapeutic use</topic><topic>Meglumine Antimoniate</topic><topic>Metabolic Clearance Rate</topic><topic>Organometallic Compounds - administration & dosage</topic><topic>Organometallic Compounds - pharmacokinetics</topic><topic>Organometallic Compounds - therapeutic use</topic><topic>Pharmacokinetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Valladares, Josep-Enric</creatorcontrib><creatorcontrib>Riera, Cristina</creatorcontrib><creatorcontrib>Alberola, Jordi</creatorcontrib><creatorcontrib>Gállego, Montserrat</creatorcontrib><creatorcontrib>Portús, Montserrat</creatorcontrib><creatorcontrib>Cristòfol, Carles</creatorcontrib><creatorcontrib>Franquelo, Carme</creatorcontrib><creatorcontrib>Arboix, Margarita</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><jtitle>Veterinary parasitology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Valladares, Josep-Enric</au><au>Riera, Cristina</au><au>Alberola, Jordi</au><au>Gállego, Montserrat</au><au>Portús, Montserrat</au><au>Cristòfol, Carles</au><au>Franquelo, Carme</au><au>Arboix, Margarita</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacokinetics of meglumine antimoniate after administration of a multiple dose in dogs experimentally infected with Leishmania infantum</atitle><jtitle>Veterinary parasitology</jtitle><addtitle>Vet Parasitol</addtitle><date>1998-02-15</date><risdate>1998</risdate><volume>75</volume><issue>1</issue><spage>33</spage><epage>40</epage><pages>33-40</pages><issn>0304-4017</issn><eissn>1873-2550</eissn><abstract>Pharmacokinetics of meglumine antimoniate in dogs with experimentally induced leishmaniosis has been investigated. After infection, dogs received a dose of 75 mg kg
−1 of meglumine antimoniate twice daily by subcutaneous injection for 10 days. Blood samples were collected throughout the treatment. No statistical differences were found in the kinetic behaviour of the drug administered as a single dose to healthy dogs and that administered as a multiple dose to infected animals. However, peak plasma concentrations (
C
max) of 30.8±12.8
μg ml
−1 found after this dosage regimen were higher than those observed after the single dose administration of 100 mg kg
−1 24 h
−1. Furthermore, sustained antimony concentrations of 1.14±0.52
μg Sb ml
−1 were detected throughout the treatment. No signs of toxicity were found in the animals treated indicating that this regimen would be very appropriate to treat canine leishmaniosis.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>9566092</pmid><doi>10.1016/S0304-4017(97)00193-3</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0304-4017 |
| ispartof | Veterinary parasitology, 1998-02, Vol.75 (1), p.33-40 |
| issn | 0304-4017 1873-2550 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_17292685 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Analysis of Variance Animals Antibodies, Protozoan - blood Antiprotozoal Agents - administration & dosage Antiprotozoal Agents - pharmacokinetics Antiprotozoal Agents - therapeutic use Control methods—Protozoa Dog Dog Diseases Dogs Drug Administration Schedule Injections, Subcutaneous Leishmania infantum Leishmaniasis, Visceral - blood Leishmaniasis, Visceral - drug therapy Leishmaniasis, Visceral - veterinary Male Meglumine - administration & dosage Meglumine - pharmacokinetics Meglumine - therapeutic use Meglumine Antimoniate Metabolic Clearance Rate Organometallic Compounds - administration & dosage Organometallic Compounds - pharmacokinetics Organometallic Compounds - therapeutic use Pharmacokinetics |
| title | Pharmacokinetics of meglumine antimoniate after administration of a multiple dose in dogs experimentally infected with Leishmania infantum |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T12%3A45%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacokinetics%20of%20meglumine%20antimoniate%20after%20administration%20of%20a%20multiple%20dose%20in%20dogs%20experimentally%20infected%20with%20Leishmania%20infantum&rft.jtitle=Veterinary%20parasitology&rft.au=Valladares,%20Josep-Enric&rft.date=1998-02-15&rft.volume=75&rft.issue=1&rft.spage=33&rft.epage=40&rft.pages=33-40&rft.issn=0304-4017&rft.eissn=1873-2550&rft_id=info:doi/10.1016/S0304-4017(97)00193-3&rft_dat=%3Cproquest_cross%3E17292685%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17292685&rft_id=info:pmid/9566092&rft_els_id=S0304401797001933&rfr_iscdi=true |